SCHEDULE: Slim Family Increases ProKidney Stake to 36%

The Slim family and Control Empresarial have increased their beneficial ownership in ProKidney Corp. to 36% following a share exchange.

Summary

• The Slim family and Control Empresarial de Capitales S.A. de C.V. reported a combined beneficial ownership of 73,842,723 shares of ProKidney Corp. Class A Common Stock.
• This ownership represents 36.0% of the total outstanding Class A Common Stock.
• The increase in ownership resulted from the exchange of 63,118,645 Paired Interests for an equivalent number of Class A Common Stock shares on April 28, 2026.
• The total outstanding share count used for calculation is 205,061,550 shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive event; while it indicates strong backing from a major investor, it is primarily a technical adjustment of existing holdings rather than a new capital injection.

Positives

• Significant increase in equity stake by a major institutional investor group, signaling long-term confidence in the company.
• Simplification of capital structure through the conversion of Paired Interests into Class A Common Stock.

Negatives

• Increased concentration of ownership may limit the free float of shares available to other investors.

Risks

• Concentrated ownership by the Slim family could influence corporate decision-making in ways that may not align with all minority shareholders.
• Market volatility associated with large block holders.

Future Outlook

The filing does not provide specific forward-looking operational guidance, focusing instead on the change in beneficial ownership and capital structure.

Industry Context

StockSavvy.ai notes that the consolidation of ownership by high-profile investors in the biotech sector often precedes strategic shifts or provides a floor for share price stability, though it may also signal a lack of near-term exit intent.

Comparison to Industry Standards

• The 36% ownership stake is significant compared to typical institutional holdings in mid-cap biotech firms, which usually range between 5% and 15%.
• The move to simplify the capital structure by converting Paired Interests to common stock is a standard governance improvement for companies transitioning from SPAC-related structures to standard corporate entities.

Corporate Governance

Related Party Transactions

• The reporting persons are members of the Slim family and their controlled entity, Control Empresarial de Capitales S.A. de C.V.

Stakeholder Impact

• Shareholders may view the increased concentration as a sign of long-term commitment.
• The reduction in complex share classes may improve transparency for investors.

Next Steps

• Continued monitoring of the Slim family's future filings for any changes in their investment position.

Key Dates

Keywords

ProKidney, Schedule 13D, Carlos Slim, Beneficial Ownership, Biotech, Equity Exchange